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COST-EFFECTIVENESS STUDY OF AN ASPIRIN
CHEMOPREVENTION ASSOCIATED OR NOT WITH A
COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL
CANCER
Francesconi C1, Benamouzig R2, Launois R1
1REES, Paris, France, 2Hopital Avicenne, Bobigny, France
OBJECTIVES: To compare the medical and economical impact
of four strategies in the prevention of colorectal cancer (CRC)
in France: (1) no treatment and no surveillance (reference strat-
egy); (2) chemoprevention with 325 mg daily aspirin; (3) colono-
scopic surveillance with a 3, 5 or 10-year periodicity; and (4) the
combination of the two latter strategies. METHODS: A Markov
decision model was built, following a ﬁctive 50-year-old cohort
during 30 years. Effectiveness was assessed by CRC incidence
and life expectancy. Transition probabilities were deﬁned after
an extensive review of literature. Only direct costs were consid-
ered. The various strategies were compared calculating incre-
mental cost-effectiveness ratios. Determinist and probabilistic
sensitivity analyses were carried out. RESULTS: Given an effec-
tiveness of chemoprevention of 25%, the most effective strategy
was the association chemoprevention and colonoscopic surveil-
lance. While 4248 CRC for 100,000 persons were expected in a
population without treatment or surveillance, 3228 CRC could
be avoided with this association, 2798 with a colonoscopic sur-
veillance and 1339 with the chemoprevention only. The more
effective the strategy was, the more expensive it was. Compared
with the reference strategy, the incremental cost-effectiveness
ratio of the chemoprevention was €3279 per life-year gained.
Compared with chemoprevention, colonoscopic surveillance
involved an incremental cost of €6611 per life-year gained. The
addition of a chemoprevention by aspirin among a screened pop-
ulation would result in an incremental cost-effectiveness ratio of
€22,000 per life-year saved. Moreover, in the 5000 Monte Carlo
simulations, the combination strategy was dominated by colono-
scopic surveillance in 16% of cases. CONCLUSIONS: The 3
strategies of prevention or screening has acceptable incremental
cost-effectiveness ratios according to the international standards.
Contrary to common opinion, primary prevention through
colonoscopic surveillance is cost-effective. Moreover, chemopre-
vention by aspirin appears to be an efﬁcient strategy when it is
associated to a colonoscopic surveillance.
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CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY
FOR PATIENTS WITH DUKES’ C COLON CANCER:
PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL—
DATA FROM CZECH PERSPECTIVE
Jiraskova L1, Dolezal T2
1Faculty of Pharmacy, Charles University, Hradec Králové, Czech
Republic, 2Charles University, Prague, Czech Republic
OBJECTIVES: Oral capecitabine is highly active drug with
favourable safety in adjuvant and metastatic colorectal cancer.
Adjuvant capecitabine is at least as effective as 5-ﬂuorouracil/leu-
covorin (5-FU/LV), with signiﬁcant superiority in relapse-free
survival and a trend towards improved disease-free and overall
survival. METHODS: We assessed the cost-effectiveness of adju-
vant capecitabine from payer (health insurance companies in
Czech Republic) and societal perspectives (including indirect
costs). We used clinical trial data and published sources to esti-
mate incremental direct and societal costs and gains in quality-
adjusted life months (QALMs). Acquisition costs were higher 
for capecitabine (99,601 CZK) than 5-FU/LV (8586 CZK), but
higher 5-FU/LV administration costs, cost of adverse events and
hospitalisation costs resulted in comparable direct costs for
capecitabine and 5-FU/LV. RESULTS: Administration costs were
signiﬁcantly higher for 5-FU/LV (by 59,500 CZK), as well as cost
of therapy for adverse effects (by 11,467 CZK). Societal costs,
including patient travel/time costs, were lower for capecitabine
group vs 5-FU/LV (cost savings 19,307 CZK), with lifetime gain
in QALMs of 9 months. Medical resource utilisation (direct
costs) are slightly higher with capecitabine vs 5-FU/LV in Czech
Republic (by 18,687). The use of a societal perspective to
measure the time and travel costs associated with the treatments
illustrates the advantage of oral over infusion treatment. Count-
ing together (direct and indirect costs) capecitabin is slightly less
costly alternative (by 624 CZK) in comparison with 5-FU/LV.
Capecitabine is also projected to increase life expectancy vs 5-
FU/LV. And from the point of view of incremental cost-utility
analysis capecitabin vs. 5-FU/LV can be considered to be domi-
nant (cost-saving and more-effective) therapy. CONCLUSIONS:
This pharmacoeconomic analysis supports the place of therapy
of capecitabine vs. 5-FU/LV in the adjuvant treatment of colon
cancer in Czech Republic.
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COST-EFFECTIVENESS OF SORAFENIB VERSUS BEST
SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA
IN SPAIN
Maroto P1,Villavicencio H2, Piñol C3, Urruticoechea L4
1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Fundació
Puigvert, Barcelona, Spain, 3Q. F. Bayer, S. A, Barcelona, Spain, 4Q. F.
Bayer, S. A, Barcelona, Spain
OBJECTIVES: To evaluate the cost-effectiveness of sorafenib plus
best supportive care (BSC) versus BSC alone in advanced renal
cell carcinoma (RCC) from the perspective of the Spanish
National Health Service. METHODS: A Markov model was
developed to project the lifetime survival and costs associated
with sorafenib plus BSC and BSC alone. The model tracked
patients with advanced RCC through three disease states—pro-
gression free survival (PFS), progression, and death. Transition
probabilities between disease states varied for each 3-month
period and were obtained from a clinical trial. Quality-Adjusted-
Life-Years (QALY) gained were used as a measure of treatment
effectiveness. Resource utilization included drug, administration,
physician visits, monitoring, and adverse events. Costs and sur-
vival beneﬁts were discounted annually at 3%. All costs were
adjusted to 2005 Euros. Scenario sensitivity analyses were con-
ducted. RESULTS: The lifetime per patient costs were €44,904
and €10,502 for sorafenib plus BSC and BSC alone, respectively.
The incremental cost-effectiveness ratio (ICER) of sorafenib plus
BSC versus BSC alone was €37,667 per QALY gained. The key
drivers of the model results were survival after progression and
PFS probabilities for both treatment groups. Sensitivity analyses
showed that the model results were robust to variance in sorafenib
and BSC treatment costs. CONCLUSIONS: Sorafenib is a cost
effective therapy in the management of advanced RCC. Sorafenib
offers a unique opportunity to prolong PFS and overall survival
in those patients, and has the potential of offer considerable value
to patients with minimal budget impact to the NHS in Spain.
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COST EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH
PEGFILGRASTIM OR FILGRASTIM IN THE MEDICAL
TREATMENT OF BREAST CANCER IN ITALY
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OBJECTIVES: Primary (ﬁrst and subsequent cycles) prophylaxis
with colony stimulating factors is recommended in the 2006
ASCO and EORTC clinical guidelines when the risk of febrile
neutropenia (FN) is ≥20%. In clinical practice ﬁlgrastim has
often been used for fewer than the recommended 11 days, which
has been shown to compromise clinical outcomes. This study has
evaluated, from an Italian perspective the cost-effectiveness of
pegﬁlgrastim vs. ﬁlgrastim (11- or 6-days) primary prophylaxis
in breast cancer patients receiving chemotherapy with ≥20% FN
risk. METHODS: We constructed a decision-analytic model
from a payer’s perspective. Direct costs were taken from ofﬁcial
price lists or literature data; they included: drugs, drug adminis-
tration, FN-related hospitalizations and subsequent medical
charges. FN risk (varied by days of ﬁlgrastim), FN case-fatality,
relative dose intensity (RDI) of chemotherapy, its impact on sur-
vival, and utility scores were based on a comprehensive litera-
ture review and expert panel validation. Breast cancer mortality
and all-cause deaths were obtained from ofﬁcial statistics. Model
robustness was tested using multi-way sensitivity analyses.
RESULTS: Pegﬁlgrastim appeared to be more effective and less
expensive than 11- and 6-day ﬁlgrastim. The average cost, risk
of FN (%), life expectancy and quality-adjusted life year (QALY)
per person for pegﬁlgrastim, 11-day ﬁlgrastim, and 6-day ﬁl-
grastim were €3316, 7%, 16.47 years, and 15.32 QALY; €5240,
12.5%, 16.41 years, and 15.27 QALY and €3630, 17.5%, 16.35
years, and 15.22 QALY, respectively. The results were sensitive
to the relative costs of drugs and FN risk. Age and cancer stage
had minimal impact. CONCLUSIONS: These preliminary 
data conﬁrm that primary prophylaxis with pegﬁlgrastim may
improve health outcomes and suggest that, in Italy, it could be
cost-saving when compared with ﬁlgrastim (also for less than 11
days). A larger application of the sensitivity analyses will be nec-
essary to further validate the model.
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A SENSITIVITY ANALYSIS OF THE COST PER QUALITY
ADJUSTED LIFE YEAR (QALY) OF TRASTUZUMAB IN THE
TREATMENT OF EARLY BREAST CANCER (EBC)
Geary U1, Lewis G2, Erny S3, Gyldmark M4, Morlotti L5,Walzer S6
1Roche Products Limited, Hertfordshire, UK, 2Roche Products
Limited, Welwyn Garden City, Herts, UK, 3F. Hoffmann-La Roche
Pharmaceuticals AG, Basel, Switzerland, 4F. Hoffmann-La Roche Ltd,
Basel, Switzerland, 5Analytica Int, Loerrach, Germany, 6Analytica
International, Loerrach, Germany
OBJECTIVES: To evaluate the sensitivity of the cost per QALY
of trastuzumab for the treatment of EBC using one-way and
probabilistic sensitivity analysis (PSA). METHODS: A 5-state
Markov model with annual transition cycles was constructed to
estimate the long-term health outcomes of EBC patients based
on results from the HERA clinical trial. Population-based utili-
ties were used for the health states in the model. NHS resource
use and costs were estimated from a consensus panel of experts
and published unit costs respectively. Costs and beneﬁts were dis-
counted at 3.5% per annum. Using the base case Markov model,
key assumptions and model parameters were varied through
plausible ranges identiﬁed in the literature to evaluate the sta-
bility of the base case cost per QALY. Key assumptions modiﬁed
in the sensitivity analysis included: 1) proportion of patients
receiving trastuzumab in the metastatic setting in both the Adju-
vant trastuzumab and No adjuvant trastuzumab arms when they
develop metastatic disease; 2) baseline patient age; 3) the dura-
tion of the treatment effect of trastuzumab; 4) the baseline risk
of disease progression. Five thousand iterations were applied in
the PSA with beta pert and beta distributions applied to the
ranges of each parameter. RESULTS: The estimated base case
cost per QALY for adjuvant trastuzumab was low at £2387.
Trastuzumab remained cost effective in all evaluated scenarios
with the cost per QALY always falling below the cost effective-
ness threshold of £30,000. The parameters with the largest
impact upon the cost per QALY were the re-treatment rate in the
metastatic setting and the duration of the treatment effect. 100%
of all iterations were below £30,000 per QALY in the PSA.
CONCLUSION: The cost per QALY of trastuzumab for the
treatment of EBC has been demonstrated to be robust and
remain below commonly accepted thresholds despite wide vari-
ations in model assumptions.
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COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION
WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN
THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK
CANCER IN SPAIN
Brosa M1, Robinson P2, Brown B2
1Oblikue Consulting, Barcelona, SC, Spain, 2IMS Health Economics &
Outcomes Research, London, UK
Deﬁnitive radiotherapy is the current standard of care for
patients with locally advanced squamous cell carcinoma of the
head and neck (SCCHN) who are contraindicated and/or not
able to tolerate the severe acute and late toxicities associated
with concomitant chemoradiotherapy. Erbitux (cetuximab) in
combination with radiotherapy has been shown to signiﬁcantly
improve patient outcomes when compared to radiotherapy alone
without aggravating the side effects of radiotherapy. OBJEC-
TIVE: To estimate the cost-effectiveness of Erbitux in combina-
tion with radiotherapy (ERT) compared to radiotherapy alone
(RT), for the treatment of locally advanced head and neck cancer
in patients for whom chemoradiotherapy is inappropriate or
intolerable in Spain. METHODS: A decision-analytic model 
was used to estimate the clinical and economic consequences 
of locally advanced SCCHN. Model parameters and health
resources use were derived from an international phase III clin-
ical trial. Costs were obtained from local data and validated by
local clinical experts. Effectiveness was measured as progression-
free survival (PFS) and QALYs gained and extrapolated beyond
trial follow-up. Costs and outcomes were discounted at an
annual rate of 3%. RESULTS: ERT was associated with an incre-
mental effectiveness of 1.17 years free of disease progression 
and 0.97 QALYs, and with additional cost per patient of about
€8777 resulting in incremental cost-effectiveness ratios of €7532
per progression-free life years and €9091 per QALY gained. The
probabilistic sensitivity analysis showed that the probability of
ERT being cost-effective at the accepted cost-effectiveness thresh-
old in Spain of €30,000 per QALY is over 99%. CONCLU-
SIONS: Cetuximab added to radiotherapy is a cost-effective
option compared to radiotherapy alone, with better outcomes at
a reasonable additional cost. Its clinical and pharmacoeconomic
proﬁle makes Cetuximab + radiotherapy the optimal treatment
for a signiﬁcant proportion of patients with locally advanced
SSCHN who are unable to tolerate or are contra-indicated to
Chemo-Radiotherapy.
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COST-EFFECTIVENESS ANALYSIS OF LETROZOLE COMPARED
TO TAMOXIFEN FOR TREATMENT OF EARLY BREAST
CANCER IN THE HUNGARIAN HEALTH CARE SETTING
Kosa J
Novartis Hungary Ltd, Budapest, Pest, Hungary
OBJECTIVE: A comprehensive decision model has been devel-
oped and adopted to the Hungarian health care settings to eval-
uate the cost-effectiveness of letrozole as adjuvant therapy for
breast cancer compared to tamoxifen. METHODS: The analy-
